| Date |
Subject |
Media |
| 2025-08-12 |
CH BIOTECH R&D Secures NT$1.2 Billion Order as New Product Heads to Indonesia
|
CH BIOTECH R&D, a leading agricultural biotechnology company, announced yesterday the global launch of its next-generation product, “Endurance Enhancer.” The company also signed a distribution agreement worth USD 42 million (approximately NT$1.2 billion) with its Indonesian partner, PT MAJU MAKMUR UTOMO (M2U). The product is expected to begin contributing to revenue starting in August. |
| 2025-08-12 |
Inventec’s Smart Healthcare Arm GOOD FUTURE BIOMEDICAL Reports Strong Progress
|
Inventec has been actively expanding into high-margin product lines such as smart healthcare in recent years. Its subsidiary, GOOD FUTURE BIOMEDICAL, has secured a firm foothold in the smart health and medical market. The company’s flagship product—its circulating tumor cell (CTC) detection system—is now being promoted in partnership with Malaysian firm Wellspring Solutions Sdn Bhd, aiming to obtain Malaysia’s Medical Device Authority (MDA) registration. Certification is expected within the year, which will further strengthen collaborations with local healthcare institutions. |
| 2025-08-11 |
Bora Pharmaceuticals Strengthens U.S. Supply Chain as Iowa Governor Visits Operations
|
Bora Pharmaceuticals announced on the 23rd that Iowa Governor Kim Reynolds successfully led a delegation to visit its manufacturing site in Maple Grove, Minnesota, as well as its U.S. pharmaceutical sales subsidiary, Upsher-Smith Laboratories. During the visit, the governor participated in a roundtable discussion and toured the facilities, focusing on the theme of “localizing pharmaceutical manufacturing” and regional supply chain integration in the U.S. Midwest. |
| 2025-08-11 |
Chi Mei Hospital Leads in Healthcare Quality with ISO 7101 Certification
|
Amid the challenges posed by an aging population, rising chronic diseases, and accelerating digital transformation, healthcare quality management is facing unprecedented pressures. Once again taking the lead in medical innovation, Chi Mei Medical Center, operated by the Chi Mei Medical Foundation, officially obtained ISO 7101 certification—the world’s first international standard dedicated to healthcare quality management—in July this year. It is now the first medical center in Taiwan to achieve this milestone, marking a new chapter in aligning Taiwan’s healthcare quality with international standards. |
| 2025-08-11 |
Taipei Veterans General Hospital’s Electronic Medical Record System Achieves U.S. Certification
|
On July 11, Taipei Veterans General Hospital (TVGH) officially passed the Stage 6 certification of the Electronic Medical Record Adoption Model (EMRAM) developed by the Healthcare Information and Management Systems Society (HIMSS). This milestone reflects the hospital’s attainment of globally advanced standards in key areas such as EMR system functionality, clinical decision support, and information security—demonstrating TVGH’s strong capabilities and tangible achievements in the realm of smart healthcare. |
| 2025-08-11 |
AlleyPin Partners with Global Pharma Data Leader IQVIA to Accelerate Digital Health Transformation in Taiwan Clinics
|
AlleyPin has officially announced a strategic partnership with IQVIA, a global leader in pharmaceutical data and technology services. The two companies will jointly promote clinic-centric digital health innovation, introducing forward-looking data applications and tech-enabled service models to Taiwan’s primary care sector. |
| 2025-08-11 |
Syncell Inc. Raises NT$750 Million in Series A Funding to Build Taiwan’s International-Class Biotech High-End Instrument Brand
|
Taiwan innovative biotech instrument company Syncell Inc. today announced the successful completion of a NT$750 million Series A funding round, led by Taiwania Capital. The round also saw participation from heavyweight investors including Everbright Biofund, National Development Fund, Abico Group, Himalaya Venture Fund, Ta Ya Venture Capital, BE Health, Isaiah Capital, Hua Nan Venture Capital, First Venture Capital, Dongan Investment, ITIC, and Taiwan Cooperative Venture Capital. The capital raised will be used to accelerate international market expansion and technology development, positioning Syncell as a leading Taiwanese biotech company creating internationally recognized high-end instruments. |
| 2025-08-11 |
HanchorBio’s Anti-Cancer Drug HCB101 to Complete International Licensing as Early as Q4 This Year, Plans to List in Q1 Next Year
|
HanchorBio-KY, a biotech company listed on the OTC market, held an investor conference on the 22nd, during which Chairman Liu Shigao shared the latest clinical progress and future outlook for its investigational anti-cancer biologic HCB101. Liu expressed optimism that HCB101 will complete overseas market licensing between Q4 this year and Q3 next year, with a projected valuation of US$1.8 billion to $2.5 billion by year-end. The company aims for a successful listing on the stock market in Q1 of next year. |
| 2025-08-11 |
BenQ Materials Advances in Medical Business, Reports Positive Results
|
BenQ Materials, a leading polarizer manufacturer, has been actively expanding its medical business in recent years. In the last quarter, revenue from its medical segment is expected to exceed 30% of total sales, helping to optimize the product mix and improve gross margin performance. |
| 2025-08-11 |
SunWay Biotech Expands Hospital Portfolio with Distribution Rights for Four Dr. Reddy’s Drugs in Taiwan
|
Bora Health, the pharmaceutical distribution arm of SunWay Biotech, has signed a collaboration agreement with global pharmaceutical leader Dr. Reddy’s Laboratories Ltd. (Dr. Reddy’s), securing exclusive distribution rights in Taiwan for four of its products. These drugs focus on therapeutic areas including infectious diseases, central nervous system (CNS) disorders, and rare diseases, significantly enhancing Bora Health’s product lineup in the hospital channel. |
